{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:37Z","timestamp":1747157857251,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T01:27:36Z","timestamp":1721438856000},"page":"e870-e877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8257-0210","authenticated-orcid":false,"given":"Ashmita","family":"Siwakoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhdev","family":"Khadka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa A.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.07.008_bib0001","unstructured":"National cancer institute surveillance epidemiology and end results program. Cancer stat facts: myeloma. Available from URL: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html [accessed August 20, 2021]."},{"issue":"5","key":"10.1016\/j.clml.2024.07.008_bib0002","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with Multiple Myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.07.008_bib0003","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1177\/0300060518757640","article-title":"Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice","volume":"46","author":"Xia","year":"2018","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.clml.2024.07.008_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.clml.2024.07.008_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0090-1229(80)90097-5","article-title":"Suppression of polyclonal immunoglobulins in Multiple Myeloma: relationship to the staging and other manifestations at diagnosis","volume":"17","author":"Pruzanski","year":"1980","journal-title":"Clin Immunol Immunopathol"},{"issue":"10","key":"10.1016\/j.clml.2024.07.008_bib0006","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2024.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.07.008_bib0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/10428194.2020.1855345","article-title":"Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients","volume":"62","author":"Geng","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.07.008_bib0009","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12185-018-2547-7","article-title":"Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation","volume":"109","author":"Gao","year":"2019","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed multiple myeloma patients: Effects on overall survival and progression free survival in the Danish population","volume":"12","author":"S\u00f8rrig","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.clml.2024.07.008_bib0011","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1080\/10428194.2017.1403026","article-title":"Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution","volume":"59","author":"Jimenez-Zepeda","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2024.07.008_bib0012","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00277-020-04068-5","article-title":"Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma","volume":"99","author":"Eisfeld","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.008_bib0013","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-018-3574-4","article-title":"Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.07.008_bib0014","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2024.07.008_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2024.07.008_bib0018","series-title":"JBI Manual for Evidence Synthesis","article-title":"Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"issue":"10","key":"10.1016\/j.clml.2024.07.008_bib0019","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"7109","key":"10.1016\/j.clml.2024.07.008_bib0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clml.2024.07.008_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.clml.2024.07.008_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"2","key":"10.1016\/j.clml.2024.07.008_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bjh.18182","article-title":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","volume":"198","author":"D\u00e1vila","year":"2022","journal-title":"Br J Haematol"},{"issue":"S1","key":"10.1016\/j.clml.2024.07.008_bib0024","first-page":"472","article-title":"EP 1026 Immunoparesis at diagnosis is an adverse prognostic factor for progression free-survival and overall survival in Multiple Myeloma","volume":"4","author":"Ribeiro","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2024.07.008_bib0025","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S2152-2650(21)02306-5","article-title":"P-179: Immunoparesis remains a negative prognostic factor in newly diagnosed Multiple Myeloma by competing risk analysis","volume":"21","author":"Moreno","year":"2021","journal-title":"Clin Lymph Myeloma Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.07.008_bib0026","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/cancers14092278","article-title":"Clinical considerations for immunoparesis in Multiple Myeloma","volume":"14","author":"Chahin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.clml.2024.07.008_bib0027","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood-2009-05-221689","article-title":"The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients","volume":"114","author":"Paiva","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:10:07Z","timestamp":1729595407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002647"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}